<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes</h2>
    <div class="badge">2025-09-09T12:08:00+00:00</div>
    <ul>
      <li>35.8% in the control group.</li>
<li>29.5% in the control group.</li>
<li>Among IBS-C patients, 67.1% of patients in the treatment group vs.</li>
<li>Among IBS-M patients, 66.0% of patients in the treatment group vs.</li>
<li>In the largest study of its kind, recently published in the June 2025 issue of Gastroenterology, inFoods IBS demonstrated the following statistically significant outcomes: 59.6% of patients in the treatment group (who el</li>
<li>09, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc.</li>
<li>As the largest study of its kind, it demonstrated statistically significant outcomes: 59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA’s endpoint for abdominal pain redu</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes\n• 35.8% in the control group.\n• 29.5% in the control group.\n• Among IBS-C patients, 67.1% of patients in the treatment group vs.\n• Among IBS-M patients, 66.0% of patients in the treatment group vs.\n• In the largest study of its kind, recently published in the June 2025 issue of Gastroenterology, inFoods IBS demonstrated the following statistically significant outcomes: 59.6% of patients in the treatment group (who el\n• 09, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc.\n• As the largest study of its kind, it demonstrated statistically significant outcomes: 59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA’s endpoint for abdominal pain redu" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/biomerica-launches-ai-backed-infoods-120800393.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>